ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CHMP/ICH/83812/2013
Published21/07/2017
Effective from01/02/2018
KeywordsImpurities, genotoxicity, mutagenic, carcinogenic
DescriptionThis guideline emphasizes considerations of both safety and quality risk management in establishing levels of mutagenic impurities that are expected to pose negligible carcinogenic risk. It outlines recommendations for assessment and control of mutagenic impurities that reside or are reasonably expected to reside in final drug substance or product, taking into consideration the intended conditions of human use.


Document history

Second version
Current version
Adopted guidelinePublished: 21/07/2017
Effective from: 01/02/2018
 
First versionAdopted guideline
 
In operation: 01/01/2016–31/01/2018

Superseded version

 

Adopted guideline


Questions and answers

In operation: 01/01/2007–31/12/2015


Published: 19/10/2010
 

Related documentApplication of the principles of the ICH M7 guideline to calculation of compound-specific acceptable intakes - Step 2bPublished: 04/08/2015

How helpful is this page?

Average rating:

 Based on 25 ratings

Add your rating:

See all ratings
5 ratings
5 ratings
5 ratings
5 ratings
5 ratings
    

Tell us more